Vera Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$315.5 | -$167.2 | -$102.0 | -$90.9 | -$34.4 |
| Net income | -$299.6 | -$152.1 | -$96.0 | -$89.1 | -$32.6 |
| Balance Sheet | |||||
| Total debt | $75.0 | $50.0 | $50.0 | $25.0 | $5.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$241.7 | -$135.7 | -$92.2 | -$67.7 | -$23.7 |
| Share repurchases | $0.0 | $<0.1 | $0.0 | — | — |
Shares outstanding 71.8M · Free float 59.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.